Johnson & Johnson’s (J&J) combination therapy of Lazcluze (lazertinib) and Rybrevant (amivantamab-vmjw) has been granted marketing authorisation by the European Commission (EC) as a first-line ...

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.

Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced ...

The combination of J&J's cancer drugs Rybrevant and lazertinib was approved in August for a type of non-small cell lung cancer (NSCLC), based on data that it helps patients live without their ...

New Option Lazertinib plus amivantamab was approved based on results from the phase III MARIPOSA trial, which compared the ...

The combination of amivantamab-vmjw and lazertinib extended OS by more than 1 year. Previously reported results showed a 30% reduction in risk for progression or death with the combination.

The combination J&J’s Rybrevant (amivantamab) with Yuhan Corp-partnered Leclaza (lazertinib) has been shown to be more effective than Tagrisso (osimertinib) on its own at extending progression ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved a Type II variation extension of indication for Rybrevant (amivantamab), in ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy for non-small cell ...